We describe the generation of a fusion cytokine consisting of GM-CSF in tandem with N-terminal-truncated MCP-1 (6-76), hereafter GMME1. Treatment of activated T cells with recombinant GMME1 protein leads to proinflammatory cytokine reduction and apoptosis via a CCR2-restricted pathway. Similarly, cell death is triggered in macrophages cultured with GMME1, while an inhibition of Ab production from plasma cells is observed. Treatment of CD4 T cells derived from experimental autoimmune encephalomyelitis mice with GMME1 leads to p38 hyperphosphorylation, inhibition of p44/42, AKT and STAT3 phosphorylation, and caspase-3 activation. GMME1 administration to experimental autoimmune encephalomyelitis mice suppresses symptomatic disease and correlates with decreased levels of inflammatory cytokines including IL-17, MOG-specific Ab titers, and blockade of CD4 and CD8 T cell infiltration in spinal cords. We propose that GMME1 defines a new class of agents for the treatment of autoimmune ailments by selectively targeting lymphomyeloid cells expressing CCR2.
C
hemokines are implicated in inflammatory responses especially at the coordination and control of immune cell trafficking (1) . These proteins usually bind to their cognate G protein-coupled receptors (GPCR) 3 initiating a proinflammatory and chemotactic response in CC receptor-expressing lymphomyeloid cells (2) (3) (4) (5) (6) . Intriguingly, CC chemokines, MCP-1 in particular (hereafter referred to as CCL2), have also been shown to be amenable to MMP processing, converting full-length CCL2 to a N-terminal-truncated derivative with potent antagonistic and antichemotactic properties relative to the parental polypeptide (7) . Indeed, we have previously demonstrated that MMP-processed CCL2 (mpCCL2) is profoundly inhibitory on Ig production by CCR2-expressing plasma cells (8) . In addition, it was previously demonstrated that the antagonist variants 5-76 as well as 6-76 of CCL2 (missing the first four or five N-terminal amino acids, respectively) were devoid of chemotactic activity (9) . However, only the 5-76 truncated CCL2 is considered as a potent antagonist, as opposed to the 6-76, because it can desensitize intact CCL2 by competing for its receptor CCR2 (9) . The CCL2 (6-76) loss of function derivative prompted us to exploit and optimize the use of this variant using the combinatorial fusion cytokine (fusokine) technology as part of a novel approach for GPCR modulation. A fusokine represents the fusion of two distinct and functionally unrelated cytokine domains as one single polypeptide that might lead to unanticipated pharmacological properties as we have previously reported (10) . Along this line of thought, we have shown that fusion of GM-CSF to IL-2 to generate the GIFT2 fusokine led to a potent proinflammatory cytokine with unanticipated prosurvival effects on NK cells, which coexpress the GM-CSF and the IL-2 receptor (11) . Our laboratory has previously demonstrated that as the N-terminal domain of a fusokine, that GM-CSF is permissive for high fusokine secretion efficiency by transfected cells (10, 11) . Furthermore, GM-CSF has a fairly long plasma half-life reported to be ϳ6 h (12, 13) , which may markedly extend the in vivo bioavailability of C-terminal domains, such as truncated CCL2. In addition, from our previous experience with another fusion protein, GIFT15, we found that the GM-CSF N-terminal domain can markedly alter the receptor binding properties of the C-terminal partner leading to unheralded cell signaling features and novel pharmaceutical properties (10) . Therefore, GM-CSF-based fusokines may lead to proinflammatory synergy or profoundly antagonistic properties to the C-terminal companion domain in manner dictated by the influence of GM-CSF on fusokine half-life, synergy with GM-CSFR-mediated signaling, and steric influence on the C-terminal fusokine partner signaling pathway. These features would allow an unanticipated gain of function for truncated CCL2 (6-76) as part of a fusion protein with GM-CSF and, thus, interesting pairing for the generation of a novel fusokine targeting cells expressing CCR2. In this study, we show that such a fusokine leads to profoundly altered signaling through the CCR2 GPCR pathway and initiates a potent proapoptotic response in CCR2-expressing lymphomyeloid cells. Although multiples trains of CCR2 Ϫ/Ϫ are susceptible to experimental autoimmune encephalomyelitis (EAE) (14) , the major consensus still suggests that selective depletion of CCR2-expressing pathogenic cells involved in autoimmune ailments such as multiple sclerosis (MS) (15) would theoretically offer selectivity and minimize off-target toxicity, as can be seen with broad action immune suppressive drugs. In this study, we demonstrate that in the EAE mouse model of MS, delivery of GMME1 is a potent suppressor of CCR2-expressing cells causative of MS/EAE, thereby validating the use of a novel class of chimeric fusokines in the selective depletion of CC-expressing cells involved in a maladapted immune response.
Materials and Methods

Reagents
All used female mice were 6 -8 wk old (The Jackson Laboratory). Recombinant proteins (rGM-CSF/rCCL2) and their Abs were purchased form R&D Systems. Ab for ␣-tubulin was purchased from Santa Cruz Biotechnology. Cleaved caspase 3, p44/42, p38, p38, AKT, and STAT3 Abs were purchased from Cell Signaling Technology. rhMMP1 was purchased from Sigma-Aldrich. All flow cytometry Abs were purchased from BD Biosciences. CCR2 primers, apoptosis detection kits, ELISA for mouse CCL2, mouse IFN-␥, mouse IL2/IL4/IL13/IL17, mouse CXCL5, and mouse TNF-␣ were purchased from R&D Systems. RNA extraction kit was purchased from Qiagen. CD3/CD28 beads and CFSE dye were purchased from Invitrogen. Contigen was purchased from Bard Urological Division. The MOG 35-55 was synthesized by Sheldon Biotech Center and CFA was obtained from Cedarlane Laboratories. The pertussis toxin was purchased from Sigma-Aldrich. CD4 and CD8 T cell enrichment kits were purchased from StemCell Technologies. Inflammatory quantitative RT-PCR (qRT-PCR) arrays were purchased from SABiosciences and used according to the manufacturer's instructions.
Fusokine design and expression
Mouse CCL2 was amplified by PCR to generate a 5 aa truncation at the N terminus then cloned into the mammalian expression vector pCMV in frame with the cDNA encoding mouse GM-CSF. HeLa cells were transiently transfected using Polyfect (Qiagen) and supernatant tested by Western blot. HeLa cells were also transfected using pGMME1 and selected with G418 for a total period of 3 wk to generate stable expression of the fusokine.
Prediction of fusokine three-dimensional model
The structural models of CCR2 and GMME1 were obtained by homology modeling using MODELLER 9v3 (University of California at San Francisco). The crystal structure of human ␤ 2 adrenergic G-protein-coupled receptor (PDB entry: 2R4R) is used as a template for CCR2 (16) . For the fusion protein GMME1, crystal structures of human GM-CSF (PDB entry: 2gmf) and CCL2 (PDB entry: 2nz1) are used as the templates for residues 21-190 in GMME1. Fold recognition method as implemented in PROS-PECT 2.0 (Oak Ridge National Laboratory) was subsequently used. The crystal structure of photosystem I protein (PDB entry: 1pse) was identified as a template. Based on templates 2gmf, 2nz1, and 1pse, 100 structure models of GMME1 were generated and the one with lowest objective function was selected for further analysis.
Induction of CCR2 expression and GMME1 effects
For CCR2 induction, CD4 T cells were purified using the Spinsep kit and cultured in 1:1 ratio with anti-CD3/CD28 beads in 96-well plates for 72 h. Cells were then washed and analyzed for CCR2 expression by RT-PCR and flow cytometry. For in vitro proliferation assays, CD4 T cells were labeled with 5 g/ml CFSE for 8 -10 min at 37°C and then washed once with complete medium and three times with PBS. To assess the proliferation induced by the CD3/CD28 beads in the presence of the fusokine over time, cells were treated with GMME1 and analyzed daily by flow cytometry. Supernatants were collected daily and assessed by ELISA for IL-2 levels.
MLR and ELISPOT
The supernatant of cocultured 10 5 splenocytes-derived from BALB/c or C57BL/6 mice for 72 h with equimolar concentrations of chemokines was centrifuged and used to detect IFN-␥ secretion by ELISA. For the MLR assay using CCR2 Ϫ/Ϫ C57BL/6 splenocytes, 10 5 splenocytes of BALB/c were fixed with paraformaldehyde before their addition to C57BL/6 splenocytes. After 3 days of culture with the test conditions, IFN-␥ levels were assessed by ELISA. ELISPOT was performed as follows: recombinant OVA-coated ELISPOT plates (Millipore) were washed three times with PBS and blocked with 1% BSA before the addition of cells under different test conditions. Following three washes with PBS, secondary anti-mouse alkaline phosphatise-labeled Abs were added for 4 h at 4°C before development.
Apoptosis analysis
Peritoneal macrophages cultured for 24 h with equimolar concentrations of rGM-CSF, rCCL2, mpCCL2, rGMCSG/rCCL2, rGM-CSF/mpCCL2, or GMME1 were lysed and whole cell lysate was loaded on a 4 -20% gradient gel and probed with anti-cleaved caspase-3 according to the manufacturer's instructions. The result obtained with GMME1 was confirmed by propidium iodine (PI) and annexin-V staining. Staining for purified CD4 and CD8 T cells was performed similarly. To generate antagonist CCL2 in vitro, 10 ng of pure rhMMP1 was added directly to 50 g pure rCCL2 in PBS for a period of 4 h at 37°C. MMP-processed CCL2 was directly used in assays without further modifications.
qRT-PCR on stimulated splenocytes
RNA was extracted from mouse cells using a Qiagen RNeasy minikit and Qiashredder columns according to the manufacturer's instructions. One microgram of RNA was reverse transcribed using RT 2 First Strand Kit and FIGURE 1. Design and expression of GMME1. A, Schematic representation of the GMME1 amino acid sequence. B, GMME1-CCR2 interaction. Structural models of CCR2 and GMME1 predicted by homology modeling and placed according to the putative interacting surfaces. CCR2 is colored according to the secondary structure and its seven transmembrane helices are labeled as TM1-TM7. The solvent-accessible surface of CCR2 is in gray transparent. GMME1 is in yellow and blue ribbons. Residues Y138, R160, P162, K163, and R174 in GMME1 (gray spheres) are the CCL2 residues implicated in the interaction with CCR2. C, Denaturing immunobloting using conditioned-medium from transiently transfected HeLa cells with GM-CSF, CCL2, or GMME1 probed with polyclonal goat anti-CCL2. Recombinant CCL2 was used as positive controls.
applied to PCR array plates, both from SABiosciences. Plates were processed in an Applied Biosystems 7500 Fast Real-Time PCR System, using automated baseline and threshold cycle detection. Data were interpreted by using SABiosciences' web-based PCR array data analysis tool.
Biochemical responses and signaling analysis
For signaling analysis, EAE-derived CD4 T cells were purified and treated for 5 min with 1 pmol of rCCL2 or GMME1 and then lysed using ice-cold cell lysis buffer before their sonication. The activation of p38, p44/42, pAKT, and pSTAT3 were probed by Western blot using 4 -20% gradient SDS-PAGE gels and appropriate Abs.
APC assays
APC assays were performed using peritoneal macrophages collected from retired breeder C57BL/6 mice. Upon binding and washing from nonadherent cells, macrophages were treated with MOG 35-55 for 24 h, then washed and fixed using paraformaldehyde before the addition of 
Gene engineering MSC to express GMME1
Whole bone marrow from femurs and tibias of CCL2 Ϫ/Ϫ C57BL/6 mice was harvested and placed in culture in complete medium until the appearance of a homogeneous MSC polyclonal population, which was later phenotyped by flow cytometry while their plasticity tested by inducing them to differentiate into osteoblasts and adipocytes (data not shown). The GMME1 cDNA was cloned in the AP2 retroviral plasmid and retropracticles generated as shown previously (10) . Concentrated retroparticles were then used to gene modify CCL2 Ϫ/Ϫ C57BL/6 MSCs. Secretion and expression levels of GMME1 by MSCs were analyzed by Western blot and CCL2 ELISA, respectively.
EAE induction and CCL2 Ϫ/Ϫ MSC-GMME1 contigen implantation
The synthetic MOG 35-55 peptide was emulsified in CFA and injected s.c. at the base of the tail. Animals also received pertussis toxin immediately after the s.c. injection by IP injections, repeated 2 days later. Mice were clinically scored every 2 days as follows: 0, no disease; 1, floppy tail; 2, hind limb weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, moribund stage. Following the appearance of EAE symptoms, all groups were normalized to possess a grade 2 average before receiving a s.c. implant of contigen-embedded MSCs as a neo-organoid as previously described by our group (17) . Contigen implants contained CCL2
Ϫ/Ϫ MSCs gene-engineered to express GMME1 or null CCL2
Ϫ/Ϫ MSC (2 ϫ 10 6 cells per implant).
Hematological and histological analysis
To investigate the levels of circulating proinflammatory cytokines, mice sera were collected weekly from treated EAE mice 1 wk following MSC implantation and tested by ELISA. For Ab titer, ELISA plates were coated with 1 mg/ml MOG peptide and then screened using diluted sera to calculate final titers. White blood cell count was performed using the Z2 coulter Particle Count and Size analyzer (BD Biosciences).
For histological analysis, mice were perfused with PBS and their spinal cords removed. For H&E staining, spinal cords were fixed, embedded, and cut. For CD4 and CD8 immunohistology, sections were frozen before cutting and staining.
Statistical analysis
The p values were calculated by paired Student t test.
Results
Engineering the GMME1 fusokine
The GMME1 fusokine was created by cloning a modified cDNA of mouse GM-CSF missing the nucleotide coding for the last 11 carboxy terminal amino acids in frame to the 5Ј end of a mouse CCL2 cDNA missing the nucleotides coding for the first five Nterminal amino acid (corresponding to aa 6 -76 of the signal peptide-free form of CCL2). An interdomain single amino acid asparagine linker was introduced. The final fusokine GMME1 cDNA encodes for a single polypeptide chain of 250 aa (Fig. 1A) . Computer-based analysis of the theoretical three-dimensional protein structure of GMME1 predicts for a direct and stable interaction of the CCL2 domain of GMME1 with CCR2 (Fig. 1B) . Denaturing immunoblotting performed on the supernatant from HeLa cells transiently transfected to express GMME1 showed that the chimeric protein is efficiently secreted in the extracellular space and has a molecular mass of 50 kDa (Fig. 1C) .
Biological effects of GMME1 on lymphomyeloid cells
Following stimulation, activated T cells are known to induce the expression of CCR2 de novo (18) . To confirm that notion, naive CD4 T cells were purified and cultured with medium alone or supplemented with beads containing anti-CD3/CD28 Abs to induce CCR2 expression as shown by RT-PCR and flow cytometry analysis ( Fig. 2A) . To determine the functional impact of GMME1 on CD3/CD28-activated CD4 T cells, CFSE-labeled CD4 lymphocytes were cultured in the presence of splenocyte-conditioned medium only or supplemented with GMME1. Interestingly, a strong proliferation of lymphocytes occurred under CD3/CD28 stimulation whereas the addition of GMME1 robustly inhibited it as seen with the CFSE peak profiles (Fig. 2B) . Because IL-2 secretion accompanies lymphocyte activation, we analyzed its levels in the supernatant of CFSE-labeled cells and noticed a strong reduction following GMME1 treatment even after CD3/CD28 stimulation (Fig. 2C ). However, GMME1 had no effect on CCR2 Ϫ/Ϫ CD4 T cells demonstrating specificity toward CCR2 (Supplemental Fig.  1) . 4 To confirm our observations, we analyzed the effect of GMME1 on physiologically activated lymphocytes. To do so, a MLR was performed using splenocytes derived from wild-type (WT) C57BL/6 mice or CCR2 Ϫ/Ϫ C57BL/6 mice as responders and paraformaldehyde-fixed BALB/c splenocytes as stimulators. The up-regulation of IFN-␥ production was measured as a surrogate marker of allo-activation of the C57BL/6 responders. We observed a significant inhibition in IFN-␥ production by WT cells when exposed to GMME1, whereas CCR2 Ϫ/Ϫ responder lymphocytes were unaffected by GMME1 treatment (Fig. 2D) . GMME1 was similarly assessed on plasma cells. Following WT or CCR2 Ϫ/Ϫ C57BL/6 mice immunization using recombinant OVA to induce an OVA-specific humoral response, their splenocytes were cultured in the presence of GMME1 before performing an OVA-specific ELIS-POT assay. A robust inhibition of Ab production was observed using both mpCCL2 (rCCL2 plus hMMP1) and GMME1 on WT Ab-secreting cells only suggesting that the fusokine is as potent as the antagonistic form of CCL2 in suppressing plasma cells expressing CCR2 (Fig. 2E) . In addition to B and T lymphocytes, macrophages are also known to express CCR2 (19), so we assessed the effect of GMME1 treatment on these cells as well. Peritoneal macrophages harvested from C57BL/6 mice and exposed to GMME1 died by apoptosis 24 h later as shown by activation of caspase-3 (Fig. 2F) as well as annexin-V/PI costaining (Fig. 2G) .
Biochemical effects of GMME1 on pathogenic lymphoid cells
To understand the molecular mechanism of GMME1 on lymphocytes involved in the pathogenesis of EAE, splenocytes collected from EAE mice were stimulated in vitro with MOG alone, in the 4 The online version of this article contains supplemental material.
FIGURE 4. GMME1 inhibits EAE.
A, Implants secreting GMME1 inhibit EAE progression and its removal did not lead to relapse (n ϭ 10 per group). B and C, The fusokine was detected in circulation up to the fifth week whereas it disappeared upon implant removal (n ϭ 5 per group and p Ͻ 0.0008). Data are shown as average Ϯ SD. D, Noticeable atrophy was observed at wk 2 post implantation whereas spleen size recovered at wk 5 once mice have recovered from EAE. E, A significant decrease in CD3 ϩ and CD19 ϩ cells were noticed only at the second week in the GMME1 group. F, GMME1 does not lead to systemic lymphomyeloid depletion in circulation as observed in the spleen. G, Splenocytes derived from mice were restimulated with MOG. Both GMME1 groups had less proliferative activity consistent with the decrease in IFN-␥ secretion (n ϭ 5 per group and p Ͻ 0.005). Data are shown as average Ϯ SD. presence of rCCL2, or a combination of rCCL2 and GMME1 to examine the effect of the fusokine under competitive conditions. A quantitative RT-PCR (qRT-PCR) array was then performed on isolated RNA to identify modulated inflammatory genes. As shown in Fig. 3A , GMME1 led to the down-regulation of IL2, IL4, IL13, and CXCL5 as well as the transcription factor T-box 21 involved in IFN-␥ induction even in the presence of rCCL2 in a 1:1 molar ratio to GMME1. All identified factors were then confirmed by ELISA (Fig. 3B) . Interestingly, following CD4 and CD8 T cells purification from EAE mice and GMME1 treatment for 48 h, almost 80% of both cell populations were seen undergoing apoptosis (Fig. 3C) . To understand GMME1's effect on molecular pathways, purified CD4 T cells stimulated for 5 min with GMME1 or rCCL2 demonstrate an asymmetrical activation of the MAPK pathway by hyperactivating p38 while inhibiting p44/42 phosphorylation (Fig.  3D) . Furthermore, GMME1 was capable of completely blocking both AKT and STAT3 activation as opposed to rCCL2 clearly showing antagonizing properties on the AKT and JAK-STAT pathways (Fig. 3D) . To examine the significance of these findings on EAE CD4 lymphocytes implicated in pathology induction, we cultured purified EAE CD4 T cells in the presence of fixed syngeneic peritoneal macrophages presenting MOG 35-55 under different test conditions. As such, macrophages act as stimulators without the capacity of secreting soluble factors that might interfere with the assay. As expected, CCL2
Ϫ/Ϫ MSC conditioned-medium significantly induced both IL-17 and IFN-␥, proinflammatory cytokines implicated in promoting EAE. However, GMME1 significantly inhibited their secretion from responder CD4 T cells (Fig. 3E) .
GMME1 delivery to EAE mice ameliorates pathology
As an experimental method to test delivery GMME1 in a continuous manner to EAE mice, we chose the use of gene-engineered mesenchymal stromal cells (MSCs) as an in vivo delivery platform. Our group has previously demonstrated that MSCs engineered to produce plasma proteins, embedded in biomatrix, and implanted s.c. form a neo-organoid, in essence a synthetic ectopic endocrine tissue, which allows for long-term delivery of proteins such as erythropoietin (17) . Because MSCs are known to secrete CCL2 and its cleaved variant (8), we used MSCs derived from CCL2 Ϫ/Ϫ mice as a cell-based platform to deliver GMME1 in vivo, thus avoiding any bias arising from contemporaneous CCL2 secretion. Therefore, to evaluate the in vivo efficacy of GMME1 under pathological conditions, C57BL/6 mice with pre-established EAE were implanted with a neo-organoid contigen implant containing CCL2
Ϫ/Ϫ MSCs gene-engineered to secrete GMME1. The continual delivery of the fusokine led to a progressive and stable recovery of EAE disease score up to 2 mo with no apparent relapse. One advantage of using neo-organoid implants is the possibility to surgically remove the implant with full reversal of in vivo protein delivery as we have previously shown (17) . Therefore, we tested whether GMME1's removal from EAE-remitted mice affected outcome. To verify whether GMME1 levels are absent from circulation upon implant removal, an ELISA was performed on mice sera at different time points. GMME1's level was detected as of the first week post implantation and persisted up to the fifth week in mice bearing the contigen implant (Fig. 4B) , whereas no detectable levels of the fusokine was observed 1 wk post removal (Fig. 4C) . Mice whose GMME1 implants were removed remained in EAE remission for duration of observation. Spleens from control or GMME1-implanted mice were analyzed at wk 2 and 5. Splenic atrophy was observed in the GMME1 group early during inflammation (wk 2), but resolved to full size at wk 5 (Fig. 4D) . Furthermore, the spleen of mice whose GMME1 implant was removed looked similar to the remaining control groups (Fig. 4D) . Flow cytometric analysis of lymphoid cells contained in the smaller spleens of GMME1-treated mice revealed a lymphodepletion of CD3 ϩ and CD19 ϩ cells occurring at wk 2 with normal levels at wk 5 once the pathology was resolved (Fig. 4E) . However, peripheral blood leukocyte counts over the same period were not significantly affected (Fig. 4F) . In vitro restimulation of splenocytes derived from treated or control EAE mice demonstrate a weak proliferation in the GMME1 or GMME1 removed implant group with a robust decrease in levels of IFN-␥ (Fig. 4G) .
Hematological and pathological analysis of EAE mice treated with GMME1
Plasma cytokine analysis show that the presence of the fusokine correlates well with the decrease in levels of proinflammatory cytokines such as TNF-␣, IFN-␥, and IL-17 in circulation (Fig. 5A) . A noticeable improvement was also obtained at the humoral level because MOG Ab titer decreased significantly in GMME1-treated mice (Fig. 5B) . One of the most important hallmarks of EAE is spinal cord infiltration by MOG-specific CD4 T cells. Once they have crossed the blood-brain barrier, CD4 T cells get reactivated by microglia cells presenting the MOG peptide leading to the induction of proinflammatory cytokines and chemokines, which in turn will amplify inflammation, neuronal damage, and recruitment of further effector immune cells (18) . Analysis of CD4 and CD8 T cell absolute cell number in the spinal cord demonstrate a large infiltration of immune cells in the EAE control group as opposed to the GMME1-treated group or in mice where the implant was removed (Fig. 5C ). The same outcome was obtained by H&E staining of spinal cords or through immunohistology for CD4 and CD8 lymphocytes (Fig. 5B) demonstrating the potency of GMME1 in robustly blocking inflammatory cell migration to the CNS most likely due to their cell death in the periphery.
Discussion
Chemokines and their receptors are involved in normal physiological immune responses but they can, under certain circumstances, participate in maladaptive pathological immune reactions (1). For example, CCR2 is largely implicated in the pathophysiology of graft-vs-host disease, EAE, inflammatory bowel disease, and other inflammatory diseases (20 -24) . As a result, CCR2 as part of the family of GPCRs, has generated considerable interest as a potential target for treatment of autoimmune and alloimmune ailments. Various difficulties, however, were encountered in generating compounds that can specifically target CCRs. For instance, the development of intrakine (25) or degrakine molecules (26) , which are specific chemokines linked to an endoplasmic reticulum retention signal sequence on their carboxy termini, have been shown to sequester target GPCRs in the endoplasmic reticulum to prevent their transport to the cell surface or induce their degradation. Even though efficient in preventing or reducing chemokine stimulation, these molecules were linked to intracellular toxicity not to mention their passive diffusion outside of the cell (27) . Nevertheless, transducing target cells is required for the success of this strategy, an approach that is unfeasible in the context of ubiquitous expression of target GPCR (27) . We are proposing in this study, a strategy enabling the direct targeting of GPCR. We chose CCR2 due to its wide involvement in various immune pathologies and expression profile on target effector cells. The developed novel fusokine, GMME1, is capable of specifically targeting CCR2 on activated T cells or macrophages leading to their cell death or inhibition of Ab production from plasma cells. In addition, GMME1 can actively compete for CCR2 in the presence of its ligand CCL2, demonstrating a high capacity for competitive antagonism leading to a blockade in inflammatory cytokine secretion.
The MAPK, AKT, and JAK-STAT pathways are important for the induction of EAE pathologies (28 -30) . One specific example is the recruitment of tyrosine kinases to CCR2 upon rCCL2 binding to CCR2 and phosphorylation of the tyrosine residue 139 promoting CCR2 homodimerization for consequent downstream signaling (31) . The sum of the unheralded biochemical effects of GMME1 demonstrate an asymmetrical signaling taking place in the MAPK pathway in addition to the complete inhibition of AKT and JAK-STAT activation leading to cellular apoptosis in a caspase-3 dependent manner. We can also conclude that GMME1 tropism seems to be CCR2 specific because C57BL/6 CCR2 Ϫ/Ϫ splenocytes were completely refractory to the biochemical effects of GMME1. The fact that GMME1 pharmacological effects are lost on CCR2
Ϫ/Ϫ cells suggest high target selectivity and we cannot invoke binding to and signaling through other CCR receptors.
In light of the potent depletion of CCR2-expressing lymphomyeloid cells induced by GMME1 in vitro, we tested whether its expression directly in vivo could lead to EAE recovery in C57BL/6 mice. We found that within a fortnight, GMME1 lead to near full recovery from symptomatic pre-established EAE. In addition, spleen atrophy observed at wk 2 post GMME1 administration is consistent with lymphomyeloid depletion and is also completely reversible as demonstrated in the spleen of mice on long-term GMME1 following implant removal.
In comparison to the previously reported antagonist derivatives of CCL2, our study demonstrates that GMME1 mechanism of action is distinct. Rather than behaving as a passive dominant negative competitive inhibitor of native CCL2 binding to CCR2, GMME1 displays novel CCR2-driven signaling which qualifies it as a distinct, bona fide, chimeric chemokine with properties diametrically opposite to that of native CCL2. Indeed, GMME1's activity usurps CCR2 signal transduction machinery and leads to subsequent apoptotic cascade. GMME1's cell biochemistry is also distinct from that of CCL2 post translational derivatives or mutants MCP-1 (9-76) (32) or 7ND (16) . These latter polypeptides are thought of as nonbiologically active decoys capable of preventing cells from responding to chemokines, blocking induction of adhesion molecules, or changes in cytoskeleton. Furthermore, P8A-MCP-1, a mutated form of CCL2, was shown to possess antagonist activity due to its ability in down-regulating the MAPK pathway, which could also be due to its binding capacity to CCR2 without triggering any further biochemical response (33) . Taken together, our experiments demonstrate that GMME1 possesses novel biochemical properties that are distinct from CCL2 and its MMPderived antagonist derivatives via its specific effect on CCR2-expressing lymphoid cells. Our results with the GM-CSF and CCL2 variant leaves open the possibility that fusokines borne of GM-CSF and alternate truncated forms of CCL2, such as 5-76, may also possess interesting biopharmaceutical properties arising from altered signaling through the CCR2 receptor.
In conclusion, GIMME1 represents the first member of a new class of chimeric cytokines which co-opts CCR2 signal transduction machinery and leads to selective and potent apoptosis of CCR2-expressing lymphomyeloid cells and consequent immune suppression. We propose that the GMME1 fusokine could be therapeutically exploited in the treatment of CCR2-driven autoimmune and alloimmune ailments as a classic protein biopharmaceutical.
